English
EN
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health data analysis, and AIO Studien gGmbH, with expertise in clinical studies and registries for oncology research, are jointly announcing the start of a pilot project as part of the AIO data hub initiative. This pilot serves as a proof of concept and is part of an evaluation process to examine the feasibility and effectiveness of advanced technologies in oncology research. Expected results: February 2024.
Drug development is a lengthy, complex, and costly process, entrenched with a high degree of uncertainty that a drug will actually succeed. The unknown pathophysiology for complex sets of diseases such as cancer, neurological disorders, and rare diseases makes target identification challenging. Since animal models often cannot recapitulate an entire disorder or disease, greater emphasis must be on human data that leads to improved target identification and validation.
Cancer research is one of the most heavily funded sectors in healthcare with global oncology spending approaching close to $200 Billion. Despite a considerable expenditure of time and resources, cancer research continues to suffer from extremely low success rates in translating preclinical discoveries into clinical practice. The continued challenges which face drug development not only drive up costs for cancer research and wasted resources, but more significantly, impact patient quality of life and survival rates.
During our Summer Cocktail on Friday, September 3rd, 2021, at Club 39, we were delighted to welcome two exceptional guest speakers:
Gunjan BhardwajEr kam nach seinem IT-Studium durch ein Stipendium nach Deutschland.(Foto: Innoplexus)